1. Home
  2. BSL vs ELTX Comparison

BSL vs ELTX Comparison

Compare BSL & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

N/A

Current Price

$12.94

Market Cap

169.3M

Sector

Finance

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.01

Market Cap

81.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
ELTX
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.3M
81.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BSL
ELTX
Price
$12.94
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
35.7K
267.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
9.55%
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$2.66
52 Week High
$14.31
$16.00

Technical Indicators

Market Signals
Indicator
BSL
ELTX
Relative Strength Index (RSI) 40.27 40.61
Support Level $12.84 $2.72
Resistance Level $13.00 $3.28
Average True Range (ATR) 0.07 0.14
MACD -0.01 0.09
Stochastic Oscillator 16.65 19.05

Price Performance

Historical Comparison
BSL
ELTX

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: